A ccording to Jacques Banchereau, PhD, director of Baylor Institute for Immunology Research (BIIR), the fi eld of cancer vaccines is in a renaissance mode. Researchers at Baylor Dallas are exploring multiple strategies to overcome the diffi culties involved in constructing therapeutic vaccines against various types of cancer. Dendritic cells, the primary antigen-presenting cells central to the cellular immune response, are being grown and manipulated in the laboratory for use as vaccines against cancer. Innovative molecular biology techniques are being used to unravel immune alterations in cancer as well as identify biomarkers of clinical effi cacy. Modern approaches are being used to stimulate the immune response and to reduce or eliminate naturally occurring immune suppressive factors. And recombinant off -shelf vaccines based on tumor-specifi c antigens grown in plants are being tested in multi-institutional clinical trials.
DENDRITIC CELL VACCINES
Under the direction of Dr. Banchereau, Karolina Palucka, MD, PhD, and Joseph Fay, MD (Figure 1 ), researchers at BIIR are developing and testing vaccines based on dendritic cells to treat a variety of cancers, including melanoma, pancreatic cancer, and breast cancer.
Dendritic cells are the master controllers of immune processes in the human body, critical for both creating and curtailing immunity. Th ey are found in all tissues and in the blood but are especially prevalent in peripheral tissues that interface with the environment (e.g., skin, mucosa). Th ere, they act as highly motile sentinels, continuously sampling their environment for potentially dangerous cells or molecules. Th ey capture and process foreign antigens, then migrate to secondary lymph organs where they activate other immune cells against the antigen. Dendritic cells are also important in the development of immune tolerance, preventing the immune system from attacking harmless substances or cells in the body. All vaccines act through dendritic cells. Even Building better cancer vaccines: researchers on the Baylor Dallas campus are using diverse approaches to optimize immune response Lorraine Cherry, PhD
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skin vaccinations depend on the vaccine encountering dendritic cells in the skin in order to elicit an immune response. Because of this critical role in directing the body's immune defense system, manipulating dendritic cells is an important strategy to pursue for cancer vaccine development.
THE BIOLOGY OF DENDRITIC CELLS
A key characteristic of dendritic cells that can be exploited in the construction of vaccines is their plasticity: they will mature diff erently in response to diff erent growth factors and cytokines. Th is variation is associated with diff erent types of T cell-mediated immune responses. In the skin, dendritic cells are present in diff erent variants (subsets), including those called Langerhans cells, which induce the proliferation of cytotoxic CD8 + T cells.
Th e maturation of dendritic cells involves two distinct aspects of immunogenicity that occur sequentially. Immature (nonactivated) dendritic cells have the ability to process antigens and to form peptide-major histocompatibility complex (MHC) complexes. However, they do not have the ability to produce
Originally published in CancerUpdate, a newsletter of the Baylor Charles A. Sammons Cancer Center. Corresponding author: Lorraine Cherry, PhD (e-mail: lorrainecherry@ earthlink.net). the costimulatory molecules needed for an immunogenic response in T cells. Th ey present self-antigens and other harmless molecules to the T cells to induce immune tolerance. Captured infections and other foreign antigens induce the further maturation of dendritic cells, which are now able to produce the costimulatory molecules needed to infl uence T-cell response. Activation factors for this process can include whole bacteria or bacterial antigens, infl ammatory cytokines, or viral products, such as double-stranded RNA. Diff erent maturation factors result in dendritic cells that direct diff erent types of subsequent lymphocyte responses.
MELANOMA VACCINES Clinical studies in patients with stage IV melanoma
Th ree approaches to melanoma vaccines have been and/ or are being investigated: (1) injecting a tumor-specifi c antigen with adjuvant, resulting in random in vivo targeting of dendritic cells; (2) injecting dendritic cells generated ex vivo from progenitor cells and loaded with tumor-specifi c antigen; and (3) injecting chimeric proteins resulting from the fusion of antidendritic cell antibodies and tumor-specifi c antigens, resulting in specifi c in vivo targeting of dendritic cells.
At BIIR, researchers have been working for over 10 years on dendritic cell vaccines that target melanoma. To date, most studies at BIIR have focused on the ex vivo generation and antigen loading of dendritic cells (Figure 2 ). For this procedure, either CD34 + stem cells or monocytes are removed from the patient's blood by apheresis and grown in culture with selected growth factors that aff ect diff erentiation and maturation. Manipulation of these ex vivo growth requirements has been directed towards achieving the desired end product: dendritic cells that are functionally similar to Langerhans cells, capable of activating CD8 + cytotoxic T cells.
Th e fi rst vaccine of this type that was tested in a clinical trial at BIIR used CD34 + precursor cells, grown with granulocyte macrophage colony-stimulating factor (GM-CSF), fetal liver tyrosine kinase 3 (FLT3) ligand, and tumor necrosis factor ␣ (TNF␣) to yield dendritic cells. (In this protocol, TNF␣ also serves as a maturation factor for dendritic cells.) For the vaccine, the cells were loaded with control proteins and with peptides derived from 4 melanoma antigens. An enhanced immune response to >2 melanoma antigens was seen in 10 out of 16 immunologically responding patients, and cytolytic DC8 + T-cell precursors specifi c for melanoma antigens were observed in 9 of 12 patients analyzed. At 10 weeks from study entry, 3 patients had no progression of disease, 4 patients with multiple lesions had regression at one or more disease sites, and 3 patients with only limited disease cleared any evidence of disease.
Th e analysis of long-term outcomes revealed an association between the breadth of melanoma-specifi c immunity and survival, i.e., patients who survived longer were those who showed the expansion of a broad repertoire of antigen-specifi c CD8 + T cells (>2 melanoma antigens presented on the DC For a second clinical trial, several important parameters in this protocol were changed. First, monocytes were used as the precursor cells and grown with GM-CSF and interleukin 4 (IL4) to yield dendritic cells. Th ese cells were activated with TNF␣ and CD40 ligand (a member of the TNF family) and then loaded with whole killed tumor cells, rather than individual peptides. Th is increases the number of potential antigens that might trigger an immune response and also increases the probability that the dendritic cells would present the antigens in a way that would be likely to generate cytotoxic CD8 + T cells. CD8 + immunity to the melanoma-specifi c antigen MART-1 was observed in 3 of 13 analyzed patients.
Two patients who mounted potent melanoma antigen-specifi c immune responses showed durable objective tumor regressions, i.e., a complete response (18 months) and a near complete response (55+ months) (overall 10% objective response rate). Both patients had failed other therapies while in stage IV.
Altogether, retrospective analysis of overall survival in a cohort of 66 patients accrued between 1999 and 2003 showed 20% long-term survival. Th ese data now need to be confi rmed in prospective randomized trials testing survival as a predefi ned clinical endpoint.
Two general observations come from these trials. First, the dendritic cell vaccines are extremely safe. Th e only common side eff ects reported were mild fl ulike symptoms for several days after the injections. Second, although a signifi cant proportion of patients showed a tumor antigen-specifi c immune response, only a few showed a durable objective tumor regression. Several mechanisms have been considered for the lack of clinical response: (1) the cytotoxic CD8 + T cells may be unable to access the antigens on the tumor cells, e.g., because of low avidity or an inability to penetrate the tumor stroma; and (2) the presence of suppressor/regulatory T cells might inhibit the functions of cytotoxic CD8 + cells in the tumor microenvironment.
Two ongoing clinical trials at BIIR are designed to test whether clinical response rates to dendritic cell vaccines in patients with stage IV melanoma can be increased by pretreating patients with low-dose cyclophosphamide to eliminate or control naturally occurring suppressor T cells.
In the 06-025 trial, the vaccine comprises dendritic cells generated from autologous monocytes using GM-CSF and interferon alpha, loaded with killed whole allogeneic melanoma cells and activated with lipopolysaccharide. Patients receive low-dose cyclophosphamide (300 mg/m 2 ) 24 hours prior to the fi rst vaccination.
In the 06-123 trial, the vaccine comprises dendritic cells generated from autologous CD34 + hematopoietic progenitors, loaded with melanoma peptides and control viral peptides and activated with lipopolysaccharide. Patients receive low-dose cyclophosphamide as described in the fi rst trial.
New clinical study in patients with stage III melanoma
For ethical reasons, most phase I/II clinical trials for novel cancer treatments are performed in advanced-stage patients who have a signifi cant tumor burden and whose disease has already progressed or recurred after multiple treatments. Unfortunately, this is the patient group that might be least likely to mount a robust immune response against their tumors, either because of poor physical status or because of depletion of their T-cell population after multiple courses of adjuvant therapy. To address this problem, researchers at BIIR are preparing to launch a clinical trial using a dendritic cell vaccine to treat patients with stage III melanoma. Patients will be recruited for this trial immediately after surgery, when they show minimal residual disease. Because the course of melanoma at this stage is somewhat indolent, a long time line will be required in this trial, with at least a 2-year follow-up.
OTHER DENDRITIC CELL VACCINES
Although the technology developed at BIIR to construct dendritic cell vaccines has focused on melanoma, it is readily adaptable to other cancer types.
Pancreatic cancer
Pancreatic cancer is the fi fth most common cause of cancer death in the United States. Th e recent deaths of high-profi le celebrities such as Luciano Pavarotti and Patrick Swayze from pancreatic cancer have sensitized the general public to the grim prognosis associated with this disease and the critical need for more eff ective treatments. A dendritic cell vaccine against pancreatic cancer should be ready for the clinic next year.
Breast cancer
Another cancer in need of more eff ective treatments is triplenegative breast cancer. Th is subtype of breast cancer is clinically negative for the expression of receptors for estrogen and progesterone and for the HER2 protein. Th us, although it can be treated with chemotherapy, it is not responsive to tamoxifen or trastuzumab. Triple-negative breast cancer has a high prevalence rate in young women and in women of African descent; it is aggressive and likely to recur after treatment.
Dr. Palucka is working to develop a dendritic cell vaccine against triple-negative tumors based on long peptides. Previous trials have loaded dendritic cells either with individual peptides or with whole killed cells. Using individual peptides is restrictive, but the use of whole cells means that much of the immune response will be diffi cult to monitor, since it is mounted against unknown antigens. CD8 + T cells typically recognize peptide fragments that are 8 to 10 amino acids long. When loaded with long peptides (20 to 50 amino acids), the dendritic cells take them up and process them into appropriately sized epitopes. In preclinical studies, Dr. Palucka is testing antigens characteristically associated with and overexpressed in cancer cells to select appropriate long peptides for this vaccine.
Human papillomavirus
Under the leadership of Gerald Zurawski, PhD, vaccination with chimeric proteins that fuse antibodies against dendritic cellspecifi c antigens with tumor cell-specifi c antigens is currently being investigated in preclinical models. Th e tumor-specifi c antigens used for the fused molecule can be either unique to a specifi c tumor or shared. While unique antigens tend to be more immunogenic, shared antigens lend themselves to a more broadly applicable vaccine that could be reproduced more cost eff ectively and made available to a wider range of patients. Th e chimeric approach has resulted in high levels of immune response in the mouse.
Baylor Research Institute recently received funding from the National Institutes of Health to investigate the use of this approach for the treatment of human papillomavirus (HPV), one of the most common sexually transmitted diseases. HPV aff ects 20 million people in the United States alone and is associated with nearly 70% of all cervical cancers. Existing vaccines against HPV are preventive and not eff ective when used in individuals already infected with the virus. With Dr. Zurawski as principal investigator, the funding will be used to create a therapeutic vaccine for the treatment of patients who are already infected with HPV. Th e vaccine will fi rst be tested in a mouse model and, if successful, will progress to a human model.
THE FUTURE OF DENDRITIC CELL VACCINES
According to Dr. Banchereau, there is growing enthusiasm about the possibility that dendritic cell vaccines will become an important tool in cancer management. Clinical trials have shown promising results and minimal toxicity from fi rst-and second-generation vaccines, and third-generation vaccines are now becoming available. New paradigms involving the treatment of early stage patients will be tested in clinical trials that measure time to progression and survival, rather than laboratory measures of immune response. "We are just at the beginning of a major revolution," said Dr. Banchereau. "Th e coming decade will see impressive changes in the way we manage cancer."
OTHER STRATEGIES FOR VACCINES: VACCINE RESEARCH AT MARY CROWLEY CANCER RESEARCH CENTER A two-pronged approach for treating non-small cell lung cancer
Historically, non-small cell lung cancer (NSCLC) has been regarded as a nonimmunogenic cancer, and strategies for developing a vaccine to treat this deadly disease have met with little success. Researchers at Mary Crowley Cancer Research Center are using the tools of molecular biology to genetically modify tumor cells to improve immune response. Under the leadership of Executive Director John Nemunaitis, MD, and Scientifi c Director Neil Senzer, MD (Figure 3) , novel strategies are being pursued to simultaneously activate the immune system and block immune inhibitors produced by cancer cells.
GVAX: genetic manipulation of the immune response
A number of cytokines, including GM-CSF, have a positive impact on immune response, especially when given intracellularly. Based on this observation, the GVAX vaccine was developed by transfecting GM-CSF into autologous cancer cells. Th e vaccine was tested in a published clinical trial involving 33 patients with NSCLC who had failed previous treatment regimens. After GVAX injection with their own transfected cancer cells, three patients had a complete response, and two of these patients continue to be in remission beyond 8 years.
A downside to the use of GVAX is that it requires that a resectable tumor sample be available from which to harvest tumor cells to create the vaccine. Th is is not possible in all patients, so researchers tested an allogeneic vaccine developed by NovaRx with cells from four NIH lung cancer cell lines using a diff erent transgene, transforming growth factor (TGF) ß2. Th e average published response rate to this new vaccine was similar to that seen with the autologous vaccine.
Five studies were carried out at Mary Crowley in which patients with NSCLC were treated with these vaccines, leading to some dramatic results. Six patients are still alive at 5 to 10 years after treatment. Importantly, there were no signifi cant side eff ects from the vaccine in any patients.
Strategies for blocking immune inhibitors
While these results were promising and suggest a survival advantage, measures to possibly increase response rates were of further interest. So, Mary Crowley investigators decided to try a blockade of TGF ß2, one of the most active inhibitors of the immune response. By incorporating an antisense oligonucleotide against TGF ß2 into cancer cell lines, they were able to get a >35% downregulation of TGF ß2 production. Th e 1-and 2-year estimated survival rates were 64% and 47% in the group of stages IIIB and IV NSCLC patients receiving the optimized doses, favorably comparing with an expected 20% survival probability in this same group of patients. A follow-up published clinical trial testing effi cacy at optimal dose confi rmed prolonged survival.
Mary Crowley is on the cusp of new vaccine development for NSCLC. Overall, it is clear that a combination approach -stimulating the immune system and blocking immune suppression-works better than either approach alone. Th ese nontoxic vaccines have been able to generate dramatic durable responses in a subset of patients, and researchers are now measuring components of the immune system to determine how a b responders differ from nonresponders. This work has also justifi ed current ongoing trials involving a novel combination plasmid of the GM-CSF and TGF ß2 knockdown genes.
Defining new targets for vaccines against breast cancer
Th e HER2 molecule is a human growth factor receptor that can promote tumor cell proliferation in a variety of epithelial cancers, including breast cancer and ovarian cancer. HER2 gene amplifi cation or protein overexpression is associated with an especially aggressive form of breast cancer.
Th e monoclonal antibody trastuzumab, directed against the extracellular domain of the HER2 molecule, is designed to target and block the function of HER2. Its clinical effi cacy is a function of direct binding to HER2, and it appears to be useful only in patients with high levels of HER2 overexpression, roughly 30% of patients with breast cancer. On the other hand, therapeutic vaccines comprising peptides from the extracellular domain of HER2 are designed to educate the immune system to attack breast cancer cells; they do not require a high level of HER2 overexpression and may be eff ective in 75% to 80% of women with breast cancer.
In early trials, patients vaccinated with the E75 peptide from the HER2 extracellular domain showed increased recurrence-free survival and a decreased rate of recurrence after responding to standard cancer therapies. Th e pattern of recurrence was signifi cant, in that vaccinated patients did not experience metastasis to the bone, a common site of early metastasis in nonvaccinated patients.
Clinicians at Mary Crowley are currently participating in two clinical trials testing diff erent vaccine strategies for the treatment of HER2-positive patients with high-risk breast (studies 08-06 and 08-07) or ovarian cancer (study 08-07). Th e vaccines used in these trials are made from smaller peptides derived from the same protein as E75. Th e GP2 peptide is HLA-A2 restricted; because it will be presented in the context of a type I MHC protein, it will serve to activate cytotoxic CD8 + T lymphocytes. Th e AE37 peptide is not HLA restricted; it will be presented in the context of a type II MHC protein and activate helper CD4 + T lymphocytes. Th e combination of CD4 + -and CD8 + -activated T lymphocytes optimizes the immune response.
Th e Mary Crowley 08-06 trial is part of a single-blinded, multicenter phase II trial sponsored by Brooke Army Medical Center comparing four treatment arms in patients with early stage node-positive or high-risk node-negative breast cancer. HLA-A2-positive patients receive either a vaccine consisting of GP2 in combination with GM-CSF or GM-CSF alone. HLA-A2-negative patients receive either a vaccine with AE37 in combination with GM-CSF or GM-CSF alone. At the time of entry into the trial, patients will have completed standard primary breast cancer therapies as appropriate for their specifi c cancer. Th ey will be clinically cancer free but considered to be at high risk for recurrence.
Th e Mary Crowley 08-07 trial is part of a multicenter phase I study evaluating the use of GP2 and AE37 given together in combination with GM-CSF for the treatment of patients with HLA-A2 + or HLA-A3 + intermediate-to high-risk HER2-positive breast or ovarian cancer. As in the 08-06 trial, breast cancer patients will have completed standard therapies and be clinically disease free. Stage IIIC or IV ovarian cancer patients will have received optimal debulking surgery and chemotherapy prior to enrollment in the trial. By including two peptides that are believed to activate the immune system in diff erent ways, it is hoped that the potency of the vaccine will be enhanced compared with using either peptide alone.
Mary Crowley is a nonprofi t clinical cancer research center off ering patients innovative cancer therapies in clinical trials under the oversight of the Food and Drug Administration. Mary Crowley focuses on new therapies targeting the molecular pathways that impact cancer growth including vaccines, gene therapy, RNA interference, and nanoparticle technology.
PLANT-BASED VACCINE TRIAL AT TEXAS ONCOLOGY
Texas Oncology physicians on the medical staff at Baylor Dallas will be participating in a phase I clinical study to evaluate the safety and tolerability of an autologous idiotype vaccine for patients with relapsed follicular lymphoma who are in complete or partial remission following salvage therapy.
Follicular lymphoma is a generally slow-growing type of non-Hodgkin's lymphoma that arises in B cells. Every B cell has unique immunoglobulins on the cell surface, and the idiotypic antibodies found on the surface of malignant B cells are highly specifi c tumor markers. Th e basis of the vaccine is to isolate these specifi c proteins from the patient, grow them in vitro, tie them to a carrier, and inject them back into the patient. Th e vaccine will be produced from the patient's own blood sample using the Magnicon technology developed by Bayer Innovation GmbH. Th is process introduces a blueprint for the desired protein into tobacco plants using a species of soil bacterium as a carrier. Th e plant can quickly produce large quantities of the protein, which is then extracted from the leaves. Because they produce few symptoms in their early stages, follicular lymphomas are usually not diagnosed until they are in advanced stages. At that point, even if treatment results in a remission, recurrences are very common. Th e aim in developing this vaccine is to keep patients in remission after they have responded well to chemotherapy. To participate in the trial, patients must have histologically proven follicular lymphoma in its fi rst clinical relapse/progression requiring treatment and must have a lymph node or tumor that can be biopsied for use in manufacture of the vaccine.
Texas Oncology/Sammons Cancer Center is one of only two clinical sites in the United States that will be participating in this international trial.
